The Captial Market (CapitalMarket.com) rating for Mankind Pharma IPO is 44. Their analysis recommends Avoid, However active risk seekers can try for the IPO.

Reviewer	Rating Score	Rating
Capital Market	44	Avoid, However active risk seekers can try

Mankind Pharma IPO Review by Dilip Davda May apply

[Dilip Davda] A major domestic player in healthcare products is going public with a pure vanilla OFS issue. It is diluting just 10% now. It has shown good financial performance from FY20 to FY22. The setback for 9m of FY23 is due to one-time provisioning for its recent takeovers. Based on recent performance, the issue appears fully priced. It’s a long race horse, hence investors may consider parking funds with a long-term perspective. Read detail review...

Mankind Pharma IPO Peer Comparison

Mankind Pharma Limited peer comparison with similar listed entities. (Consolidated) (As on March 31, 2022)

Company Name	EPS (Rs)		NAV (per share) (Rs)	P/E (x)	RoNW (%)
Company Name	EPS Basic	EPS Diluted	NAV (per share) (Rs)	P/E (x)	RoNW (%)
Mankind Pharma Limited	33.20	35.78	153.65		23.29
Sun Pharmaceuticals Industries Limited		13.60	200.10	71.54	6.82
Cipla Limited		31.17	258.32	28.18	12.08
Zydus Lifesciences Limited		43.83	166.05	10.95	26.40
Torrent Pharmaceutical Limited		22.97	175.89	66.25	13.06
Alkem Laboratories		137.63	722.44	23.03	19.05
JB Chemicals & Pharmaceuticals Limited		49.82	240.83	39.48	18.06
Eris Lifesciences Limited		29.88	140.39	19.10	21.28
Ipca Laboratories Limited		34.85	216.47	22.38	16.10
Abbott India Limited		375.86	1,327.00	56.19	28.32
Glaxosmithkline Pharmaceuticals Limited		100.04	157.19	57.03	63.64
Dabur India Limited		9.81	47.41	54.55	20.75
Procter & Gamble Health Limited		116.00	371.39	42.27	31.23
Zydus Wellness Limited		48.54	761.26	31.11	6.38

Notes for listed peers:

Diluted EPS is sourced from the financial statements of the respective company for the year ended.
P/E Ratio has been computed based on the closing market price of equity shares on the National Stock Exchange of India Limited on March 24, 2023, divided by the Diluted EPS.
For listed peers, RoNW is computed as profit after tax for the year divided by closing net worth. Net worth has been considered as the total equity attributable to equity holders.
Net Asset Value ("NAV") is computed as the closing net worth divided by the equity shares outstanding as on March 31, 2022.
For Proctor & Gamble Health Limited, the latest financial statements are for the year ended June 30, 2022. Accordingly, revenue from operations, EPS, RoNW, and NAV pertain to the year ending June 30, 2022.
Torrent Pharmaceuticals Limited has announced a 1:1 bonus issue with an ex-bonus date on July 08, 2022. Accordingly, Diluted EPS for the year ended March 31, 2022, has been adjusted to reflect the bonus issue.

Mankind Pharma IPO Review by Members

Mankind Pharma IPO Reviews, analysis and views by popular members. Read Mankind Pharma Ltd. IPO reviews by retail investors to find recommended ipo to buy.

Mankind Pharma IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid
Count	0	0	0	0
%	0.00	0.00	0.00	0.00

Member	Review
No recommendation found. Be the first to post the recommendation.

Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.

Mankind Pharma IPO Review & Recommendations

Mankind Pharma IPO Review Summary from brokers and analysts

Mankind Pharma IPO Capital Market Rating

Mankind Pharma IPO Review by Dilip Davda May apply

Mankind Pharma IPO Peer Comparison

Mankind Pharma IPO Review by Members

Mankind Pharma IPO Review Summary by Members

Read more about Mankind Pharma IPO